Yixi Biotech specializes in providing advanced solutions in the intestinal microbiology sector. The company distributes three main research and development pipelines targeting diabetes, depression, and tumor reconstitution after chemotherapy, with a strong emphasis on intestinal microbes and human health. Their research spans the health mechanisms of intestinal microecology, the interaction between intestinal immune microenvironments and disease, and the development of alternative treatments, synthetic biological strains, and drugs for intestinal microbial diseases.
Founded in 2019, Yixi Biotech operates in the Biotechnology and Health Care industries. The company recently secured a CNY100.00M seed round investment on 22 August 2023. The investment was led by Oriza Holdings, Clivia Capital, Oasis Capital, Shenzhen High-tech Investment and Equity Investment Fund Management, Nanwan Baiao Fund, Winguide Huangpu Pharmaceutical, and Yizhan Capital.
As a venture capitalist, it's essential to keep an eye on Yixi Biotech due to its innovative approach in addressing significant health issues through the study of intestinal microbiology. The recent substantial seed round investment and the reputable lineup of investors also indicate confidence in the company's potential. This makes Yixi Biotech an intriguing prospect for further observation and potential investment consideration.
